LAVAL, QC, Aug. 28 /CNW/ - Labopharm Inc. (TSX: DDS, NASDAQ:DDSS) today
announced that its New Drug Submission (NDS) for its once-daily formulation of
tramadol has been accepted for review by the Therapeutic Products Directorate
of Health Canada. The NDS is subject to a targeted 300-day review period.
